SYLATRON
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $356,443 | 1 | 0 |
| 2018 | $796,425 | 23 | 0 |
| 2017 | $755,977 | 15 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 38 | 100.0% |
| Food and Beverage | $54.78 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron Peginterferon alfa-2b and Actimmune Interferon gamma-1b in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | Merck Sharp & Dohme Corporation | $653,479 | 0 |
| Combination of MK3475 and Pegylated Interferon alfa-2b for Advanced Melanoma | Merck Sharp & Dohme Corporation | $531,142 | 0 |
| Combination of MK3475 and Pegylated Interferon alfa-2b for Advanced Melanom | Merck Sharp & Dohme Corporation | $449,883 | 0 |
| Combination of MK3475 and Pegylated Interferon alfa-2b for Advanced Melanoma. | Merck Sharp & Dohme Corporation | $209,390 | 0 |
| A phase II multi-center study evaluating the Combination Immunotherapy for advanced cholangiocarcinoma with pembrolizumab and PEG-Intron | Merck Sharp & Dohme Corporation | $64,895 | 0 |
Top Doctors Receiving Payments for SYLATRON
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $1.9M | 38 |
| , MD | Specialist | Bethlehem, PA | $54.78 | 1 |
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.9M
- Total Doctors 1
- Transactions 39
About SYLATRON
SYLATRON is a biological associated with $1.9M in payments to 1 healthcare providers, recorded across 39 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $356,443 was paid across 1 transactions to 0 doctors.
The most common payment nature for SYLATRON is "Unspecified" ($1.9M, 100.0% of total).
SYLATRON is associated with 5 research studies, including "Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron Peginterferon alfa-2b and Actimmune Interferon gamma-1b in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer" ($653,479).